What is the name of the research project selected by AMED involving stem cells from exfoliated deciduous teeth?

The research project is titled 'Development of a Novel Treatment for Hypoganglionosis Using Human Exfoliated Deciduous Tooth-Derived Stem Cells' and was selected by AMED for FY2026.

Which company is collaborating with Kyushu University on the clinical study using SHED for hypoganglionosis?

S-Quatre Co., Ltd. is collaborating with Kyushu University on the clinical study for hypoganglionosis using SHED as a research collaborator.

Who is the principal investigator of the hypoganglionosis study at Kyushu University Hospital?

Lecturer Koichiro Yoshimaru of the Department of Pediatric Surgery at Kyushu University Hospital is the principal investigator of the study.

What role does S-Quatre play in the AMED-funded clinical research project on hypoganglionosis?

S-Quatre is responsible for manufacturing and quality control of SHED and contributes expertise in cell manufacturing and clinical development for the project.

Why are SHED considered promising for treating hypoganglionosis in the clinical study?

SHED secrete abundant growth factors and cytokines that are expected to promote nerve growth, making them a promising therapeutic approach for hypoganglionosis.

AI News NQ Analysis

Clinical Study Using Stem Cells from Human Exfoliated Deciduous Teeth for Hypoganglionosis Selected by AMED

NQ Score 90/100

AI Summary (NQ-processed)

S-Quatre, a group company, has been selected by the Japan Agency for Medical Research and Development (AMED) to conduct a clinical study on using stem cells from human exfoliated deciduous teeth (SHED) to treat hypoganglionosis. This research, conducted in collaboration with Kyushu University, aims to develop a new therapeutic approach for this intractable disease, for which no effective treatment currently exists.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the name of the research project selected by AMED involving stem cells from exfoliated deciduous teeth?: A: The research project is titled 'Development of a Novel Treatment for Hypoganglionosis Using Human Exfoliated Deciduous Tooth-Derived Stem Cells' and was selected by AMED for FY2026.
Q: Which company is collaborating with Kyushu University on the clinical study using SHED for hypoganglionosis?: A: S-Quatre Co., Ltd. is collaborating with Kyushu University on the clinical study for hypoganglionosis using SHED as a research collaborator.
Q: Who is the principal investigator of the hypoganglionosis study at Kyushu University Hospital?: A: Lecturer Koichiro Yoshimaru of the Department of Pediatric Surgery at Kyushu University Hospital is the principal investigator of the study.
Q: What role does S-Quatre play in the AMED-funded clinical research project on hypoganglionosis?: A: S-Quatre is responsible for manufacturing and quality control of SHED and contributes expertise in cell manufacturing and clinical development for the project.
Q: Why are SHED considered promising for treating hypoganglionosis in the clinical study?: A: SHED secrete abundant growth factors and cytokines that are expected to promote nerve growth, making them a promising therapeutic approach for hypoganglionosis.